Phase III trials of Alzheimer's drug are halted

Share this content:

Pfizer, Johnson & Johnson and Elan said all Phase III tests of Alzheimer's drug bapineuzumab are being halted after the drug failed to hit its goals for cognition and global function. The tests involved the infusion form of the drug and were being conducted among patients with mild to severe forms of the neurological disease. The announcement came just 15 days after the companies said the drug also had failed to hit endpoints in another Phase III trial.